Jade Biosciences Appoints Dr. Edward Conner as CMO Ahead of JADE101 Phase 1 Data
Jade Biosciences named Edward R. Conner as Chief Medical Officer to lead its clinical and medical teams, directing development strategy and data generation for its autoimmune pipeline. His appointment aligns with interim biomarker-rich Phase 1 data for JADE101, a Phase 2 trial in IgA nephropathy and clinic entry of JADE201/JADE301.
1. Appointment Details
Jade Biosciences named Edward R. Conner as Chief Medical Officer effective April 22, 2026, tasking him to lead the clinical and medical teams. He will oversee development strategy and data generation for the company’s autoimmune pipeline.
2. Dr. Conner’s Background
Conner brings extensive clinical development experience, having served as CMO at Ardelyx, Third Harmonic Bio, Locanabio and Sangamo Therapeutics, and as a Medical Director at Genentech. He holds an M.D. from UCSF and completed a fellowship in clinical immunology.
3. Impact on Pipeline Milestones
His appointment coincides with interim biomarker-rich Phase 1 data for lead candidate JADE101, the planned Phase 2 trial in IgA nephropathy and the planned clinical entry of JADE201 and JADE301. This leadership change aims to accelerate key research timelines.
4. R&D Leadership Structure
In addition to Conner’s hire, Jade expanded Dr. Andrew King’s duties to President of R&D, reflecting a broader strategic role. These moves aim to bolster cross-functional coordination across Jade’s pipeline development teams.